Aggressive Initial Management in Early Psoriatic Arthritis: Does Adding Golimumab to Methotrexate and Steroids Offer Superior Outcomes?
Posted inDermatology news Rheumatology

Aggressive Initial Management in Early Psoriatic Arthritis: Does Adding Golimumab to Methotrexate and Steroids Offer Superior Outcomes?

The GOLMePsA trial found no significant difference in disease activity at 24 weeks when adding golimumab to methotrexate and steroids for early PsA. However, the triple therapy significantly reduced the need for rescue corticosteroids, highlighting potential steroid-sparing benefits in early intervention.
Systemic Sclerosis Pregnancies: High Livebirth Rates Mask Significant Risks of Placental Insufficiency and Postpartum Disease Progression
Posted innews OB/GYN & Women's Health Rheumatology

Systemic Sclerosis Pregnancies: High Livebirth Rates Mask Significant Risks of Placental Insufficiency and Postpartum Disease Progression

The French GR2 prospective study reveals that while 91% of pregnancies in systemic sclerosis result in livebirths, patients face significantly higher risks of pre-eclampsia, fetal growth restriction, and severe postpartum hemorrhage, with nearly 40% experiencing maternal disease worsening.